Physician profile
Anna Friend
NPI 1902287972
$1,161.94
in general payments reported to CMS, 2019-2025
10 companies · $408 in 2025
The $408 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $90.72 · 2023: $88.68 · 2024: $574 · 2025: $408.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,071.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,071.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $567.23 | 2024-2025 | Airsupra, Breztri, Farxiga |
| Lilly USA, LLC | $165.42 | 2022-2024 | Mounjaro |
| Abbvie INC. | $133.46 | 2023-2025 | |
| Glaxosmithkline, LLC. | $78.08 | 2023-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Phathom Pharmaceuticals, INC. | $67.49 | 2024 | Voquezna |
| Edwards Lifesciences Corporation | $38.57 | 2025 | Sapien 3 Ultra Resilia |
| Boehringer Ingelheim Pharmaceuticals, INC. | $36.55 | 2024 | Jardiance |
| Novo Nordisk INC | $33.98 | 2023-2024 | Rybelsus, Ozempic, Wegovy |
| Sanofi Pasteur INC. | $25.57 | 2024 | |
| Otsuka America Pharmaceutical, INC. | $15.59 | 2025 | Rexulti |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anna Friend listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.